Indications |
Oral Hypertension Adult: Initially, 80 mg once daily, increased to 160 mg once daily. Max: 320 mg daily. Elderly: > 75 yr: Initially, 40 mg once daily.
Oral Heart failure Adult: 40 mg bid, may be increased to 160 mg bid if tolerated. Renal impairment: Use with caution. Hepatic impairment: Severe hepatic impairment, cirrhosis, or biliary obstruction: contra-indicated. Oral Post myocardial infarction Adult: Start as early as 12 hr after MI in stable patients, at an initial dose of 20 mg bid, increased over a few wk up to 160 mg bid if tolerated. Renal impairment: Use with caution. Hepatic impairment: Mild to moderate: max: 80 mg bid. Patients with severe hepatic impairment, cirrhosis or biliary obstruction: Avoid. Special Populations: Care should be exercised with dosing of valsartan in patients with hepatic or severe renal impairment. Moderate to severe renal impairment (creatinine clearance < 20 mL/min), intravascular vol depletion or hepatic impairment: 40 mg once daily. |
||||
Contraindications |
Hypersensitivity; severe hepatic impairment, cirrhosis or biliary obstruction; primary hyperaldosteronism. Pregnancy (2nd and 3rd trimesters) and lactation. | ||||
Warnings / Precautions |
Volume depletion; renal artery stenosis; monitor serum potassium concentrations; severe CHF; renal impairment; mild to moderate hepatic impairment. Elderly. | ||||
Adverse Reactions |
Dizziness; headache; dose-related orthostatic hypotension; rash; angioedema; hyperkalaemia; myalgia; resp tract disorders; back pain; GI disturbances; fatigue; increase in BUN and serum creatinine; abdominal pain; dry cough; LFT elevations. Potentially Fatal: Blood dyscrasias (e.g. neutropenia). |
||||
Overdose Reactions |
Symptoms: Hypotension, tachycardia or bradycardia, depressed level of consciousness, circulatory collapse and shock. Management: Treatment is mainly supportive. Haemodialysis is not likely to be useful. | ||||
Drug Interactions |
Increased risk of renal impairment and hyperkalaemia with NSAIDs and ciclosporin. Increased risk of hypotension with general anaesthetics, clozapine, dopamine agonists and other antihypertensives. Increased risk of lithium toxicity. Increased risk of hyperkalaemia with potassium-sparing diuretics, potassium supplements, ACE inhibitors, heparin. See Below for More valsartan Drug Interactions |
||||
Mechanism of Actions |
Valsartan, an angiotensin II receptor antagonist, produces its BP lowering effects by antagonizing angiotensin II-induced vasoconstriction, aldosterone release and renal reabsorption of sodium. Onset: 2 hr. Duration: >24 hr. Absorption: Rapidly absorbed with oral bioavailability 23%. Peak plasma concentrations: 2-4 hr. Food may decrease the rate and extent. Distribution: Protein binding: 94-97% to serum albumin. Volume of distribution after IV admin: 17 L. Metabolism: Not significantly metabolised. Excretion: Excreted via bile in faeces (about 83% of dose) and urine (about 13% of dose), mainly as unchanged drug and some as metabolites (20% of dose). Terminal elimination half life: 5-9 hr. |
||||
Administration |
May be taken with or without food. |
||||
Storage Conditions |
Oral: Store between 15-30°C (59 - 86<249>F). | ||||
ATC Classification |
C09CA03 - valsartan ; Belongs to the class of angiotensin II antagonists. Used in the treatment of cardiovascular disease. | ||||
Storage |
Oral: Store between 15-30°C (59 - 86<249>F). | ||||
Available As |
|
Valsartan
Post Review about Valsartan Click here to cancel reply.
Valsartan Containing Brands
Valsartan is used in following diseases
Drug - Drug Interactions of Valsartan
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.